Cover Image
市場調查報告書

GeNeuro SA- 產品平台檢討

GeNeuro SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293974
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
GeNeuro SA- 產品平台檢討 GeNeuro SA - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 24 Pages
簡介

GeNeuro SA是總公司設置於瑞士的生物科技企業,擁有針對神經系統疾病治療藥的產品平台。提供針對發炎及內在性反轉錄病毒相關退化性疾病,及多發性硬化症,思覺失調症等神經系統疾病的治療藥。

本報告提供GeNeuro SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

GeNeuro SA的基本資料

  • GeNeuro SA概要
  • 主要資訊
  • 企業資料

GeNeuro SA:R&D概要

  • 主要的治療範圍

GeNeuro SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

GeNeuro SA:開發中產品概況

  • 臨床階段的開發中產品
    • PhaseⅡ產品/聯合治療模式
    • PhaseⅠ產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

GeNeuro SA:藥物簡介

  • GNbAC-1
  • Monoclonal Antibody for CIDP
  • GNbAC-2
  • Monoclonal Antibody for Diabetes

GeNeuro SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

GeNeuro SA:開發暫停中的計劃

GeNeuro SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07080CDB

Summary

Global Markets Direct's, 'GeNeuro SA - Product Pipeline Review - 2015', provides an overview of the GeNeuro SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GeNeuro SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GeNeuro SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GeNeuro SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GeNeuro SA's pipeline products

Reasons to buy

  • Evaluate GeNeuro SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GeNeuro SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GeNeuro SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GeNeuro SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GeNeuro SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GeNeuro SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GeNeuro SA Snapshot
    • GeNeuro SA Overview
    • Key Information
    • Key Facts
  • GeNeuro SA - Research and Development Overview
    • Key Therapeutic Areas
  • GeNeuro SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • GeNeuro SA - Pipeline Products Glance
    • GeNeuro SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • GeNeuro SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • GeNeuro SA - Drug Profiles
    • GNbAC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for CIDP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GNbAC-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GeNeuro SA - Pipeline Analysis
    • GeNeuro SA - Pipeline Products by Target
    • GeNeuro SA - Pipeline Products by Route of Administration
    • GeNeuro SA - Pipeline Products by Molecule Type
  • GeNeuro SA - Recent Pipeline Updates
  • GeNeuro SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GeNeuro SA, Key Information
  • GeNeuro SA, Key Facts
  • GeNeuro SA - Pipeline by Indication, 2015
  • GeNeuro SA - Pipeline by Stage of Development, 2015
  • GeNeuro SA - Monotherapy Products in Pipeline, 2015
  • GeNeuro SA - Phase II, 2015
  • GeNeuro SA - Phase I, 2015
  • GeNeuro SA - Preclinical, 2015
  • GeNeuro SA - Discovery, 2015
  • GeNeuro SA - Pipeline by Target, 2015
  • GeNeuro SA - Pipeline by Route of Administration, 2015
  • GeNeuro SA - Pipeline by Molecule Type, 2015
  • GeNeuro SA - Recent Pipeline Updates, 2015
  • GeNeuro SA, Subsidiaries

List of Figures

  • GeNeuro SA - Pipeline by Top 10 Indication, 2015
  • GeNeuro SA - Pipeline by Stage of Development, 2015
  • GeNeuro SA - Monotherapy Products in Pipeline, 2015
  • GeNeuro SA - Pipeline by Top 10 Target, 2015
  • GeNeuro SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top